Genome Research Limited

Genome Research Limited

The Institute and the wider Wellcome Genome Campus operate under the name of Genome Research Limited (GRL). GRL was established in 1992 and is a wholly owned subsidiary of the Wellcome Trust. In 2012, the Wellcome Trust Board of Governors agreed to place all activities on the Wellcome Genome Campus, including the Sanger Institute, under the auspices of GRL in order to facilitate the development of a long term and coherent strategy for the Campus and all activities on it.

Through the activities of the Wellcome Trust Sanger Institute and the wider Genome Campus, the ambition of GRL over the next 20 years is to strengthen its well-established scientific foundations and to build on them, such that the Wellcome Genome Campus becomes an international centre for scientific, business, cultural and educational activities emanating from Genomes and BioData. To achieve this vision GRL’s Mission is to:

  • Advance understanding of biology using genome sequences and biodata.
  • Apply genome science for human health and other societal benefits.
  • Foster discussion of the scientific, medical and wider implications of genomes.

Genome Research Limited Board of Directors

Professor Jeremy Farrar (Chair)

Jeremy Farrar is Director of the Wellcome Trust and leads the Trust's Executive Board. Previous to this appointment, he was Professor of Tropical Medicine and Global Health at Oxford University, Global Scholar at Princeton University and Director of the Wellcome Trust's Major Overseas Programme in Vietnam.

Professor Dame Kay Davies

Kay Davies is Dr Lee's Professor of Anatomy and Associate Head, Development, Impact and Equality, Medical Sciences Division, University of Oxford, and Honorary Director of the MRC Functional Genomics Unit. She is Deputy Chair of the Wellcome Trust Board of Governors.

Professor Rolf Heuer

Rolf Heuer is ex Director General of CERN.

Mr Tim Livett

Tim Livett is Chief Financial Officer at the Wellcome Trust. After graduating in chemistry, Tim joined ICI/Zeneca and trained as an accountant. He then spent the majority of his career in commercial aviation, working for British Airways and, after a short break, Virgin Atlantic - most recently in the role of Chief Financial Officer.

Dr Tim Rink

Tim Rink used to chair the Strategy Panel of the Technology Transfer Division of the Wellcome Trust and has been a board member of a number of US and UK biotechnology companies.

Professor Patrick Vallance

Patrick Vallance is Senior Vice President, medicines discovery and development at GlaxoSmithKline, where he joined in 2006 as head of drug discovery. Before joining GSK, Patrick led the Division of Medicine at University College London.